FI83966C - Foerfarande foer framstaellning av farmaceutiskt aktiva hyaluronsyrasalter. - Google Patents

Foerfarande foer framstaellning av farmaceutiskt aktiva hyaluronsyrasalter. Download PDF

Info

Publication number
FI83966C
FI83966C FI861395A FI861395A FI83966C FI 83966 C FI83966 C FI 83966C FI 861395 A FI861395 A FI 861395A FI 861395 A FI861395 A FI 861395A FI 83966 C FI83966 C FI 83966C
Authority
FI
Finland
Prior art keywords
hyaluronic acid
salt
molecular weight
sulfate
equivalents
Prior art date
Application number
FI861395A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI83966B (fi
FI861395A (fi
FI861395A0 (fi
Inventor
Valle Francesco Della
Aurelio Romeo
Silvana Lorenzi
Original Assignee
Fidia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36694284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI83966(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IT48980/85A external-priority patent/IT1184675B/it
Application filed by Fidia Spa filed Critical Fidia Spa
Publication of FI861395A0 publication Critical patent/FI861395A0/fi
Publication of FI861395A publication Critical patent/FI861395A/fi
Application granted granted Critical
Publication of FI83966B publication Critical patent/FI83966B/fi
Publication of FI83966C publication Critical patent/FI83966C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
FI861395A 1985-04-05 1986-04-01 Foerfarande foer framstaellning av farmaceutiskt aktiva hyaluronsyrasalter. FI83966C (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IT8547924A IT1229075B (it) 1985-04-05 1985-04-05 Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
IT4792485 1985-04-05
CN85102921 1985-04-09
CN85102921A CN85102921B (zh) 1985-04-05 1985-04-09 制备具有药物作用的透明质酸组份及含该组份的药物的方法
IT4898085 1985-12-23
IT48980/85A IT1184675B (it) 1985-12-23 1985-12-23 Procedimento per la preparazione di sali dell'acido ialuronico

Publications (4)

Publication Number Publication Date
FI861395A0 FI861395A0 (fi) 1986-04-01
FI861395A FI861395A (fi) 1986-10-06
FI83966B FI83966B (fi) 1991-06-14
FI83966C true FI83966C (fi) 1991-09-25

Family

ID=36694284

Family Applications (1)

Application Number Title Priority Date Filing Date
FI861395A FI83966C (fi) 1985-04-05 1986-04-01 Foerfarande foer framstaellning av farmaceutiskt aktiva hyaluronsyrasalter.

Country Status (27)

Country Link
US (1) US4736024A (US07923587-20110412-C00001.png)
EP (2) EP0197718B2 (US07923587-20110412-C00001.png)
JP (2) JP2585216B2 (US07923587-20110412-C00001.png)
KR (1) KR910006810B1 (US07923587-20110412-C00001.png)
CN (1) CN85102921B (US07923587-20110412-C00001.png)
AR (1) AR245369A1 (US07923587-20110412-C00001.png)
AT (1) ATE98495T1 (US07923587-20110412-C00001.png)
AU (1) AU592077B2 (US07923587-20110412-C00001.png)
BE (1) BE904547A (US07923587-20110412-C00001.png)
CA (2) CA1341418C (US07923587-20110412-C00001.png)
CH (1) CH672886A5 (US07923587-20110412-C00001.png)
DE (1) DE3689384T3 (US07923587-20110412-C00001.png)
DK (1) DK149886A (US07923587-20110412-C00001.png)
ES (1) ES8800055A1 (US07923587-20110412-C00001.png)
FI (1) FI83966C (US07923587-20110412-C00001.png)
FR (1) FR2579895B1 (US07923587-20110412-C00001.png)
HU (1) HU204202B (US07923587-20110412-C00001.png)
IE (1) IE64440B1 (US07923587-20110412-C00001.png)
IL (1) IL78263A0 (US07923587-20110412-C00001.png)
IN (1) IN165867B (US07923587-20110412-C00001.png)
IT (1) IT1229075B (US07923587-20110412-C00001.png)
LU (1) LU86386A1 (US07923587-20110412-C00001.png)
NO (1) NO174277C (US07923587-20110412-C00001.png)
NZ (1) NZ215676A (US07923587-20110412-C00001.png)
PH (1) PH29979A (US07923587-20110412-C00001.png)
PT (1) PT82342B (US07923587-20110412-C00001.png)
ZA (1) ZA862463B (US07923587-20110412-C00001.png)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1186772B (it) * 1985-10-10 1987-12-16 Crinos Industria Farmaco Composto ad attivita' pilostimolante
WO1987005517A1 (en) * 1986-03-14 1987-09-24 Bio-Technology General Corp. Heavy metal salts of hyaluronic acid useful as antimicrobial agents
US5145841A (en) * 1987-03-19 1992-09-08 Arthropharm Pty. Limited Anti-inflammatory compounds and compositions
US5668116A (en) * 1987-03-19 1997-09-16 Anthropharm Pty. Limited Anti-inflammatory compounds and compositions
ATE66133T1 (de) * 1987-05-20 1991-08-15 Ueno Seiyaku Oyo Kenkyujo Kk Kondom.
PT87886B (pt) * 1987-07-01 1993-09-30 Genentech Inc Metodo para a prevencao de deposicao de fibrina ou de formacao de adesoes e processo para a preparacao de composicoes terapeuticas para esse fim
US5055298A (en) * 1987-12-01 1991-10-08 Chemisches Laboratorium Dr. Kurt Richter Gmbh Cosmetic composition comprising an extracellular connective tissue matrix
JPH01213227A (ja) * 1988-02-23 1989-08-28 Tadashi Koyake 軟膏剤及び液剤
IT1219587B (it) * 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US4981955A (en) * 1988-06-28 1991-01-01 Lopez Lorenzo L Depolymerization method of heparin
JPH0232013A (ja) * 1988-07-20 1990-02-01 Denki Kagaku Kogyo Kk 点鼻剤
JPH02200624A (ja) * 1989-01-30 1990-08-08 Nippon Kayaku Co Ltd 歯科用包帯剤
US6458774B1 (en) * 1989-02-24 2002-10-01 Richter Gedeon Vegyeszeti Gyar Rt. Compositions containing hyaluronic acid associates and a process for preparing same
HU203372B (en) 1989-02-24 1991-07-29 Richter Gedeon Vegyeszet Process for producing hyaluronic associates and pharmaceutical compositions and cosmetics comprising such active ingredient
US5472950A (en) * 1989-02-24 1995-12-05 Richter Gedeon Vegyeszeti Gyar Rt. Compositions containing cobalt hyaluronic acid complex
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
JP2945993B2 (ja) * 1989-12-05 1999-09-06 武田薬品工業株式会社 外用剤
US5141928B1 (en) * 1989-12-20 1995-11-14 Brujo Inc Ophthalmic medication
NL8903155A (nl) * 1989-12-23 1991-07-16 Stamicarbon Harssamenstelling op basis van een polyesterhars, een aminohars en een epoxyhars.
WO1991011992A1 (en) * 1990-02-13 1991-08-22 Zerega Gere S Di Peritoneal induced medicaments
IT1240316B (it) * 1990-02-21 1993-12-07 Ricerca Di Schiena Del Dr. Michele G. Di Schiema & C. Composizioni a base di acido ialuronico ad alto peso molecolare somministrabili per via topica per il trattamento di infiammazioni del cavo orale ,per la cosmetica e l'igiene del cavo orale
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5990096A (en) * 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
CA2061566C (en) * 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids
IT1243435B (it) * 1990-10-05 1994-06-10 Altergon Sa Composizioni farmaceutiche per uso topico comprendenti acido ialuronico sale sodico e sostanze disinfettanti
US5492936A (en) * 1990-11-30 1996-02-20 Allergan, Inc. Bimodal molecular weight hyaluronate formulations and methods for using same
US5234914A (en) * 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
WO1994007505A1 (en) * 1991-07-03 1994-04-14 Norpharmco Inc. Use of hyaluronic acid and forms to prevent arterial restenosis
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5834444A (en) * 1991-07-03 1998-11-10 Hyal Pharmaceutical Corporation Hyaluronic acid and salts thereof inhibit arterial restenosis
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
AU3658793A (en) * 1992-02-10 1993-09-03 Allergan, Inc. Bimodal molecular weight hyaluronate formulations and methods for using same
US5942498A (en) * 1992-02-20 1999-08-24 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6218373B1 (en) 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
US5767106A (en) * 1992-02-21 1998-06-16 Hyal Pharmaceutical Corporation Treatment of disease and conditions associated with macrophage infiltration
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
CA2130762C (en) * 1994-08-24 1999-07-06 Eva Anne Turley Treatment of disease and conditions associated with macrophage infiltration
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
IT1263144B (it) * 1993-02-04 1996-08-01 Lanfranco Callegaro Composizioni farmaceutiche comprendenti materiale spugnoso costituito da derivati esterei dell'acido ialuronico in associazione con altre sostanze farmacologicamente attive
EP0613907A3 (en) * 1993-03-04 1995-05-24 Genzyme Ltd Controlled reduction of the polymer molecular weight.
US5616568A (en) * 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
JP4010574B2 (ja) * 1994-12-05 2007-11-21 電気化学工業株式会社 皮膚外用剤
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
CA2154103C (en) * 1995-07-18 1998-02-24 Samuel Simon Asculai Treatment of mucous membrane disease, trauma or condition and for the relief of pain
ZA966579B (en) * 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
IT1287227B1 (it) * 1996-04-04 1998-08-04 Fidia Spa In Amministrazione S Acido ialuronico quale componente del liquido di conservazione della cornea
US5939047A (en) * 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
US6451326B2 (en) 1996-05-02 2002-09-17 Burt D. Ensley Cosmetic compositions
HU225991B1 (en) * 1997-04-29 2008-02-28 Richter Gedeon Nyrt Use of the zinc hyaluronate associate (complex) for the preparation of pharmaceutical compositions for oral use against peptic ulcer
IT1287967B1 (it) * 1996-10-17 1998-09-10 Fidia Spa In Amministrazione S Preparazioni farmaceutiche per uso anestetico locale
US5843186A (en) * 1996-12-20 1998-12-01 Implemed, Inc. Intraocular lens with antimicrobial activity
US5789571A (en) * 1997-01-15 1998-08-04 Biocoat Incorporated Method of making free acids from polysaccharide salts
US20050090662A1 (en) * 1997-01-15 2005-04-28 Beavers Ellington M. Method of making free acids from polysaccharide salts
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
ATE229038T1 (de) * 1997-04-04 2002-12-15 Fidia Advanced Biopolymers Srl N-sulfatierte hyaluronsäureverbindungen, ihre derivate und verfahren zu ihrer herstellung
US6123957A (en) * 1997-07-16 2000-09-26 Jernberg; Gary R. Delivery of agents and method for regeneration of periodontal tissues
AU758370B2 (en) * 1997-08-08 2003-03-20 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6711436B1 (en) 1997-08-08 2004-03-23 Duke University Compositions, apparatus and methods for facilitating surgical procedures
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6346536B1 (en) 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US6395749B1 (en) 1998-05-15 2002-05-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, methods, and compositions for inhibiting PARP activity
JP2002193830A (ja) * 1998-10-19 2002-07-10 High Chem Co Ltd 経鼻投与用医薬製剤
DK172900B1 (da) * 1998-12-18 1999-09-27 Per Julius Nielsen Præparat samt kit til brug ved intraoculære operationer
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
EP1140198B1 (en) 1999-01-13 2007-10-31 Alchemia Oncology Pty Limited Use of hyaluronan for the manufacture of a medicament for the enhancement of the efficacy of cytotoxic drugs
CA2361268C (en) * 1999-02-01 2014-06-10 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
AU2001264595A1 (en) 2000-05-19 2001-12-03 Guilford Pharmaceuticals Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
US6348475B1 (en) 2000-06-01 2002-02-19 Guilford Pharmaceuticals Inc. Methods, compounds and compositions for treating gout
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US6828308B2 (en) * 2000-07-28 2004-12-07 Sinclair Pharmaceuticals, Ltd. Compositions and methods for the treatment or prevention of inflammation
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
US6726898B2 (en) 2000-11-17 2004-04-27 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US6576226B1 (en) 2000-11-17 2003-06-10 Gary R. Jernberg Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
ITMI20010708A1 (it) * 2001-04-03 2002-10-03 Alessandro Randazzo Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter
AR034371A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
MXPA04001828A (es) * 2001-08-27 2005-03-07 Meditech Res Ltd Protocolos terapeuticos mejorados.
HU229442B1 (hu) * 2001-09-19 2013-12-30 Takeda Gmbh Nem-szteroid gyulladásgátlók és PDE4 inhibitorok kombinációi és alkalmazásuk
ITMI20021666A1 (it) 2002-07-26 2004-01-26 Jasper Ltd Liability Co Derivati dell'acido ialuronico
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
WO2005016386A1 (en) * 2003-08-19 2005-02-24 Meditech Research Limited Improved therapeutic protocols
US20050043251A1 (en) * 2003-08-20 2005-02-24 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US7625581B2 (en) * 2003-12-19 2009-12-01 Ethicon, Inc. Tissue scaffolds for use in muscoloskeletal repairs
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
JP2007518804A (ja) 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
FR2865651B1 (fr) * 2004-01-29 2007-09-28 Fabre Pierre Dermo Cosmetique Compositions topiques associant des fragments de hyaluronate de sodium et un retinoide utiles en dermatologie cosmetique et medicale
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
GB0416397D0 (en) * 2004-07-22 2004-08-25 Glaxo Group Ltd Pharmaceutical formulations
EP1791523B1 (en) * 2004-09-21 2013-10-23 AMO Groningen B.V. Method for the preparation of a viscoelastic solution
SE0402272D0 (sv) 2004-09-21 2004-09-21 Amo Groningen Bv Methods of treating a body site with a viscoelastic preparation
EP1721602A1 (en) * 2005-05-11 2006-11-15 The Jordanian Pharmaceutical Manufacturing Co. Controlled release oral drug delivery system
FR2888752B1 (fr) * 2005-07-22 2007-10-05 Fabre Pierre Dermo Cosmetique Complexe d'association intermoleculaire d'un transporteur et d'un principe actif
CA2616607C (en) * 2005-07-27 2015-06-02 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US8623354B2 (en) * 2005-09-07 2014-01-07 Alchemia Oncology Pty Limited Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US20070065515A1 (en) * 2005-09-22 2007-03-22 Key Douglas J Methods and compositions for treating skin lines and wrinkles and improving skin quality
JP4555232B2 (ja) * 2006-01-25 2010-09-29 Ｈｏｙａ株式会社 組織の蛍光染色方法
US8668676B2 (en) 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
CA2654255A1 (en) * 2006-06-28 2008-01-03 Novozymes Biopolymer A/S Compositions with several hyaluronic acid fractions for cosmetic and medical uses
WO2008003321A2 (en) * 2006-07-07 2008-01-10 Novozymes Biopolymer A/S Compositions with several hyaluronic acid fractions for cosmetic use
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
ES2621876T3 (es) 2006-09-13 2017-07-05 Enhance Skin Products Inc. Composición cosmética para el tratamiento de la piel y procedimientos de la misma
AU2008210557B2 (en) 2007-01-30 2013-08-01 Cypress Pharmaceutical, Inc. Hyaluronate compositions
US20090068122A1 (en) * 2007-09-06 2009-03-12 Shira Pilch Dentifrice Compositions for Treating Xerostomia
PL2818184T3 (pl) 2007-11-16 2019-06-28 Aclaris Therapeutics, Inc. Kompozycje i sposoby do leczenia plamicy
KR20110017365A (ko) * 2008-05-30 2011-02-21 페어필드 클리니컬 트라이얼즈 엘엘씨 피부 염증 및 변색을 위한 방법 및 조성물
WO2010003797A1 (en) * 2008-07-09 2010-01-14 Novozymes Biopharma Dk A/S Hyaluronic acid for corneal wound healing
CA2739243C (en) 2008-10-02 2017-08-22 L.R.R.& D. Ltd. Wound dressing comprising polymeric foam matrix and a hydrophilic polysaccharide disposed therein
CN101385874B (zh) * 2008-10-23 2012-11-28 武汉大学 一种含有高分子透明质酸的生物滑液的制备方法
US8545554B2 (en) 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
CN102458420A (zh) * 2009-05-11 2012-05-16 以色列耶路撒冷希伯来大学伊索研究发展公司 脂质-聚合物共轭物及其制备和用途
TWI383796B (zh) 2009-08-14 2013-02-01 Holy Stone Healthcare Co Ltd Use of hyaluronic acid mixture for the treatment and prevention of peptic ulcer and duodenal ulcer
TWI516269B (zh) 2009-08-14 2016-01-11 禾伸堂生技股份有限公司 使用於炎症性腸疾病（ｉｂｄ）治療和預防之透明質酸混合物
US8722644B2 (en) 2010-01-04 2014-05-13 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing peptic ulcer and duodenal ulcer
US8575130B2 (en) 2010-01-04 2013-11-05 Holy Stone Healthcare Co., Ltd. Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US9029347B2 (en) 2010-08-05 2015-05-12 Holy Stone Healthcare Co., Ltd. Method and mixture for treating and preventing inflammatory bowel disease
IT1407283B1 (it) * 2010-12-06 2014-04-04 Paoli Ambrosi De Nuovo composto di carnosina
CZ303548B6 (cs) 2011-01-05 2012-11-28 Contipro Pharma A.S. Zdravotní prípravek tvorící jód, zpusob jeho prípravy a bandáž, která jej obsahuje
CZ22394U1 (cs) 2011-03-11 2011-06-20 Contipro C, A.S. Antimikrobiální smes a kryt pro podporu hojení ran s antimikrobiálním úcinkem
HUE037474T2 (hu) 2011-07-07 2018-08-28 Holy Stone Healthcare Co Ltd Készítmény gyulladással kapcsolatban rendellenesség kezelésében és megelõzésében történõ alkalmazásra
EP2545925B1 (en) 2011-07-12 2018-02-14 Holy Stone Healthcare Co.,Ltd. Compositions comprising hyaluronic acid for treating and preventing mucosa related diseases
ITMI20111747A1 (it) 2011-09-28 2013-03-29 Fidia Farmaceutici Composizioni farmaceutiche topiche comprendenti aciclovir
ITPD20120173A1 (it) 2012-05-31 2013-12-01 Fidia Farmaceutici "nuovo sistema di rilascio di proteine idrofobiche"
JP2014141475A (ja) * 2012-12-27 2014-08-07 Daiichi Sankyo Co Ltd 新規美白剤
KR101412776B1 (ko) * 2013-03-11 2014-07-01 가톨릭대학교 산학협력단 각결막염 치료용 점안제 조성물 및 이의 제조 방법
CN103319627A (zh) * 2013-07-10 2013-09-25 南宁中诺生物工程有限责任公司 一种对透明质酸钠进行分子量分级的方法
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
CN106456584A (zh) * 2014-02-11 2017-02-22 阿拉西斯医药公司 用于矫正老视的药理学眼科用组合物和其施用
EP2910255A1 (en) * 2014-02-19 2015-08-26 MedSkin Solutions Dr. Suwelack AG Methods for the production of biopolymers with defined average molecular weight
US9603867B2 (en) * 2015-03-03 2017-03-28 Yung Shin Pharm. Ind. Co., Ltd. Pharmaceutical composition for improving wound healing or prophylactically preventing or inhibiting scar formation
ITUB20152542A1 (it) * 2015-07-28 2017-01-28 Altergon Sa Formulati oftalmici a base di complessi cooperativi di acido ialuronico a basso e alto peso molecolare
CN108603115A (zh) * 2016-02-12 2018-09-28 来姆有限公司 神经生长促进剂及其制造方法、内服剂、培养基用添加剂、细胞稀释液用添加剂、培养基、细胞稀释液、抗氧化剂及其制造方法、外用剂、以及伤口治疗剂及其制造方法
BR112019002967A2 (pt) 2016-08-19 2019-05-14 Orasis Pharmaceuticals Ltd. composição farmacêutica oftálmica, métodos de corrigir presbiopia, de reduzir o tamanho de uma pupila, de induzir miose, de aumentar a profundidade de campo, de diminuir a grandeza de aberrações de ordem superior e de melhorar a acuidade visual não corrigida de perto e de longe, implante, e, kit.
CN106727246A (zh) * 2017-02-08 2017-05-31 上海元茵生物科技有限公司 小牛血清细胞营养液
CN107802597B (zh) * 2017-12-08 2020-07-31 北京诺康达医药科技股份有限公司 一种玻璃酸钠组合物及其制备方法和应用
CN111727035B (zh) * 2018-01-18 2024-05-28 费斯制药股份有限公司 包含比拉斯汀、β-环糊精和至少一种胶凝剂的眼用组合物
FR3086865B1 (fr) * 2018-10-04 2023-04-28 Matthieu Leconte Preparation ophtalmique et lentille d'orthokeratologie pour l'inhibition, la prevention et/ou la limitation de la progression de la myopie

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583096A (en) * 1949-01-15 1952-01-22 Searle & Co Process for the production of high viscosity hyaluronic acid
DE1047380B (de) * 1954-08-18 1958-12-24 American Home Prod Verfahren zur Herstellung einer hyaluronidasefreien, teilweise depolymerisierte Hyaluronsaeure enthaltenden waessrigen Traegerloesung fuer Arzneimittel
GB818336A (en) * 1956-06-22 1959-08-12 Erba Carlo Spa A new acid aminopolysaccharide and a process for the production thereof
FR1425265A (fr) * 1962-05-14 1966-01-24 Parke Davis & Co Procédé de préparation d'un nouveau polysaccharide et de ses sels
FR3715M (fr) * 1964-06-11 1965-11-29 Lucien Nouvel Antithermiques et antirhumatismaux améliorés.
US3887703A (en) * 1967-03-24 1975-06-03 Oreal Mucopolysaccharides, their preparation and use in cosmetic and pharmaceutical compositions
US3792164A (en) * 1970-03-31 1974-02-12 Chemway Corp Ophthalmic composition comprising water-soluble alkaloid salts of polyuronic acids
GB1283892A (en) * 1970-06-08 1972-08-02 Irwin Irville Lubowe Improvements in and relating to medicinal compositions for application to the skin and/or hair
DE2364373A1 (de) * 1973-12-22 1975-07-10 Hahn Carl Dr Gmbh Pharmazeutische und kosmetische praeparate zur aeusserlichen anwendung
US3936081A (en) * 1974-02-27 1976-02-03 R & G Sloane Manufacturing Co., Inc. Pipe joint and method of making same
US4141973A (en) * 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
HU172937B (hu) * 1975-12-18 1979-01-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh proizvodnykh khondroitin-sernoj kisloty s mestno anestezirujuhhim ehffektom
SE7901565L (sv) * 1979-02-21 1980-08-22 Pharmacia Ab Medel for immunisering
JPS55153711A (en) * 1979-05-19 1980-11-29 Pola Chem Ind Inc Cosmetic lotion
HU185926B (en) * 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
US4272522A (en) * 1979-10-15 1981-06-09 Balazs Endre A Method for stimulating phagocytic activity and synergistic compositions therefor
US4303676A (en) * 1980-03-21 1981-12-01 Balazs Endre A Hyaluronate based compositions and cosmetic formulations containing same
JPS5885813A (ja) * 1981-11-17 1983-05-23 Toyo Jozo Co Ltd 吸収性良好な製剤
JPS57183707A (en) * 1981-05-02 1982-11-12 Shiseido Co Ltd Cosmetic
US4359458A (en) * 1981-09-28 1982-11-16 American Cyanamid Company O-β. -D (and O-α.. -D) Multigalactopyranosyl, xylopyranosyl and glucopyranosyl sulfate salts
JPS591405A (ja) * 1982-06-28 1984-01-06 Shiseido Co Ltd 乳化組成物
JPS597106A (ja) * 1982-07-06 1984-01-14 Shiseido Co Ltd 乳化組成物
JPS5920212A (ja) * 1982-07-27 1984-02-01 Shiseido Co Ltd 乳化組成物
JPS5939338A (ja) * 1982-08-30 1984-03-03 Shiseido Co Ltd 乳化組成物
IT1212892B (it) * 1983-10-11 1989-11-30 Della Valle Francesco Acido ialuronico ottenuto per mezzodi filtrazione molecolare sprovvisto di attivita' infiammatoria e sua utilizzazione terapeutica
JPS59219209A (ja) * 1983-05-28 1984-12-10 Kanebo Ltd 皮膚化粧料
AU555747B2 (en) * 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
DE3461292D1 (en) * 1983-08-12 1987-01-02 Ciba Geigy Ag Monoclinic lead chromate pigments
DE3334595A1 (de) * 1983-09-24 1985-04-18 B. Braun Melsungen Ag, 3508 Melsungen Wirkstoffdepot
DE3482812D1 (de) * 1983-10-11 1990-08-30 Fidia Spa Fraktionen von hyaluronsaeure mit pharmazeutischer aktivitaet, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
JPS61180723A (ja) * 1985-02-06 1986-08-13 Sanwa Kagaku Kenkyusho:Kk 易吸収性カリジノゲナ−ゼ製剤用組成物
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
WO1991011992A1 (en) * 1990-02-13 1991-08-22 Zerega Gere S Di Peritoneal induced medicaments

Also Published As

Publication number Publication date
LU86386A1 (fr) 1986-09-02
AR245369A1 (es) 1994-01-31
PT82342A (en) 1986-05-01
NO174277C (no) 1994-04-13
CA1341418C (en) 2003-01-21
NO861331L (no) 1986-10-06
CH672886A5 (US07923587-20110412-C00001.png) 1990-01-15
ES553714A0 (es) 1987-11-16
EP0197718B2 (en) 2001-07-25
JP2677778B2 (ja) 1997-11-17
IT1229075B (it) 1991-07-17
DE3689384T3 (de) 2003-05-15
FI83966B (fi) 1991-06-14
IT8547924A0 (it) 1985-04-05
EP0197718A2 (en) 1986-10-15
IL78263A0 (en) 1986-07-31
CN85102921A (zh) 1986-10-08
DK149886D0 (da) 1986-04-02
CA1340825C (en) 1999-11-23
ES8800055A1 (es) 1987-11-16
HUT40579A (en) 1987-01-28
HU204202B (en) 1991-12-30
ATE98495T1 (de) 1994-01-15
FI861395A (fi) 1986-10-06
DE3689384D1 (de) 1994-01-27
PT82342B (pt) 1988-03-03
AU592077B2 (en) 1990-01-04
DE3689384T2 (de) 1994-07-07
KR910006810B1 (ko) 1991-09-02
JPS61236732A (ja) 1986-10-22
JP2585216B2 (ja) 1997-02-26
FR2579895B1 (US07923587-20110412-C00001.png) 1990-11-23
DK149886A (da) 1986-10-06
IN165867B (US07923587-20110412-C00001.png) 1990-02-03
EP0555898A2 (en) 1993-08-18
US4736024A (en) 1988-04-05
NZ215676A (en) 1989-08-29
IE64440B1 (en) 1995-08-09
AU5566286A (en) 1986-10-16
EP0555898A3 (en) 1993-10-20
EP0197718B1 (en) 1993-12-15
FI861395A0 (fi) 1986-04-01
NO174277B (no) 1994-01-03
BE904547A (fr) 1986-10-03
IE860847L (en) 1986-10-05
FR2579895A1 (US07923587-20110412-C00001.png) 1986-10-10
EP0197718A3 (en) 1987-09-09
JPH09169667A (ja) 1997-06-30
KR860008202A (ko) 1986-11-12
PH29979A (en) 1996-10-29
CN85102921B (zh) 1988-06-08
ZA862463B (en) 1987-12-30

Similar Documents

Publication Publication Date Title
FI83966B (fi) Foerfarande foer framstaellning av farmaceutiskt aktiva hyaluronsyrasalter.
US5442053A (en) Salts and mixtures of hyaluronic acid with pharmaceutically active substances, pharmaceutical compositions containing the same and methods for administration of such compositions
DK175661B1 (da) Polysaccharidestere
FI96610B (fi) Menetelmä hyaluronihapon täydellisesti tai osittain silloitettujen esterien valmistamiseksi
JP2611159B2 (ja) ヒアルロン酸薬理活性画分、その製造方法および医薬組成物
US8088916B2 (en) Hyaluronic acid-methotrexate conjugate
US20080025950A1 (en) Modified Macromolescules and Associated Methods of Synthesis and Use
PL157922B1 (en) Method of obtaining alginic esters
US20070203094A1 (en) Esters Of Hyaluronic Acid With Rhein, Process For Their Preparation And Compositions Comprising The Same
HU190687B (en) Process for preparing new antithrombotic of polysaccharide base further pharmaceutical compositions containing such substance as active material
CA3150864A1 (en) New peptides
ES2254645T3 (es) Derivados del polisacarido k5 altamente sulfatados y su preparacion.
CA1341087C (en) Medicaments including hyaluronic acid as a drug delivery system
EP0552593A1 (en) Use of hyaluronic acid as ocular prosthesis lubricant
JP2004002369A (ja) 医薬組成物
JP2002003384A (ja) 成長因子誘導剤
WO2024057154A1 (en) Process for conjugation of hyaluronic acid and conjugates of hyaluronic acid so obtained
JP2585216C (US07923587-20110412-C00001.png)
CS245797B2 (cs) Způsob výroby muramylpeptidů

Legal Events

Date Code Title Description
QB Licence granted / registered
FG Patent granted

Owner name: FIDIA FARMACEUTICI S.P.A.

MA Patent expired